Effect of Rosiglitazone on the Differential Expression of Diabetes-associated Proteins in Pancreatic Islets of C57Bl/6 lep/lep Mice
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The insulin sensitizer drug, rosiglitazone, has been shown to have a protective effect on pancreatic islet cell structure and function in animal models of type 2 diabetes. The identification of new molecular targets associated both with islet cell dysfunction and protection is a crucial research goal. In the present study, a proteomics approach has been used to identify such targets. Obese C57Bl/6J lep/lep mice and lean littermates were given the insulin sensitizer drug BRL49653, rosiglitazone. It normalized the impaired glucose tolerance in lep/lep mice but had no significant effect on glucose tolerance in the lean mice. Pancreatic islet polypeptides were arrayed by a two-dimensional gel electrophoresis system that separated more than 2500 individual spots. Three overexpressed and six underexpressed proteins were significant (p < 0.05) between lep/lep and lean mice, and four were modulated significantly (p < 0.05) by the rosiglitazone treatment of the obese mice. The identity of these differentially expressed proteins was made using mass spectrometric analysis and provided evidence that differential expression of actin-binding proteins may be an important aspect of defective islet function. Rosiglitazone increased carboxypeptidase B expression in both lep/lep and normal mice suggesting that this might be an independent effect of rosiglitazone that contributes to improved insulin processing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of neuropeptide Y in the antiobesity action of the obese gene product
Stephens, T. W., Basinski, M., Bristow, P. K., Bue-Valleskey, J. M., Burgett, S. G., Craft, L., Hale, J., Hoffmann, J., Hsiung, H. M., Kriauciunas, A., et al. (1995) · Nature · doi:10.1038/377530a0 · Cited by 1,498
Ward, W. K., LaCava, E. C., Paquette, T. L., Beard, J. C., Wallum, B. J., & Porte, D. (1987) · Diabetologia · doi:10.1007/bf00296991 · Cited by 275
Gerich, J. E. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s117 · Cited by 264
Cited by
Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics
Rabbani, N., Xue, M., & Thornalley, P. J. (2016) · Glycoconjugate Journal · doi:10.1007/s10719-016-9705-z · Cited by 169
Advanced glycation endproducts and its receptor for advanced glycation endproducts in obesity
Gaens, K. H., Stehouwer, C. D., & Schalkwijk, C. G. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835aea13 · Cited by 166
“In animal models of obesity, GLO1 was decreased in liver [47], in glomeruli [48] and in neuronal tissue [49].”
BackgroundGlyoxalase 1 Modulation in Obesity and Diabetes
Rabbani, N., & Thornalley, P. J. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7424 · Cited by 102
Nyblom, H. K., Bugliani, M., Fung, E., Boggi, U., Zubarev, R., Marchetti, P., & Bergsten, P. (2009) · Journal of Proteome Research · doi:10.1021/pr9006816 · Cited by 33
Metadata
- Authors
- Sanchez, J.-C., Converset, V., Nolan, A., Schmid, G., Wang, S., Heller, M., Sennitt, M. V., Hochstrasser, D. F., & Cawthorne, M. A.
- Venue
- Molecular & Cellular Proteomics
- Publisher
- Elsevier BV
- Published
- 2002-07
- Volume
- 1
- Issue
- 7
- Pages
- 509-516
- ISSN
- 1535-9476 (ISSN-L)
- OpenAlex
- W2114276605
- Cited by
- 77
- References
- 3
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Rosiglitazone on the Differential Expression of Diabetes-associated Proteins in Pancreatic Islets of C57Bl/6 lep/lep Mice. https://app.cochat.ai/papers/10.1074/mcp.m200033-mcp200
- The paper
- Sanchez, J.-C., Converset, V., Nolan, A., Schmid, G., Wang, S., Heller, M., Sennitt, M. V., Hochstrasser, D. F., & Cawthorne, M. A. (2002). Effect of Rosiglitazone on the Differential Expression of Diabetes-associated Proteins in Pancreatic Islets of C57Bl/6 lep/lep Mice. Molecular & Cellular Proteomics. https://doi.org/10.1074/mcp.m200033-mcp200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.